Pascal Deschatelets, Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 95,364 shares at $61.88 ($5.9M) on 2024-03-08, disclosed to the SEC on 2024-03-11.
Scheduled sale ($5.9M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $61.88 | 42,750 | $2.6M | 44.5% |
| 2 | $62.69 | 26,257 | $1.6M | 27.7% |
| 3 | $62.69 | 26,257 | $1.6M | 27.7% |
| 4 | $63.35 | 100 | $6K | 0.1% |
| Total | $62.33 avg | 95,364 | $5.9M | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $51K | — | Filing → |
| APLS | SELL | 2025-01-30 | $24K | — | Filing → |
| APLS | SELL | 2025-01-23 | $240K | — | Filing → |